Downregulation of Dlc-1 Gene by Promoter Methylation During Primary Colorectal Cancer Progression

Haixia Peng,Feng Long,Zhiyuan Wu,Yimin Chu,Ji Li,Rong Kuai,Jing Zhang,Zhihua Kang,Xinju Zhang,Ming Guan

DOI: https://doi.org/10.1155/2013/181384

2013-01-01

BioMed Research International

Abstract:Purpose.DLC-1is a tumor suppressor gene frequently silenced in human cancers. However, the pathogenicity ofDLC-1epigenetic silencing in the mucosa-adenoma-carcinoma transformation process of colorectal cancer (CRC) has not been studied.Methods. Promoter methylation status ofDLC-1was evaluated in 4 human CRC cell lines, 48 normal mucosa, 57 adenomas, and 80 CRC tissues with methylation-sensitive high-resolution melting analysis (MS-HRMA), while the mRNA expression was examined by qPCR. HRMA was utilized to detect theKRAScodon 12, 13 andBRAFV600Emutations.Results. Partial (1%–10%) and extensive (10%–100%)DLC-1promoter methylations were observed in 10% and 0% of normal mucosa, 46% and 14% of adenomas, and 60% and 36% of CRCs, respectively. The promoter methylation ofDLC-1was related with the reduction of gene expression and the advanced Duke’s stages (Stage C and D).DLC-1promoter methylation andKRASmutations are common concurrent pathological alternations.Conclusions. Epigenetic alternation plays a key role in the transcriptional silencing ofDLC-1. It is also an independent risk factor related to the carcinogenesis of colorectal tumors and spans over its pathogenesis process. Therefore,DLC-1promoter methylation quantitation may have a promising significance in the evaluation and management of CRC patients.